The capacity for sustained self-renewal -the generation of daughter cells having the same regenerative properties as the parent cell -is the defining feature of hematopoietic stem cells (HSCs). Strong evidence exists that selfrenewal of HSC is under extrinsic biological control in vivo. A variety of cytokines, morphogenic ligands and associated signaling components influence self-renewal in culture and in vivo. Specific homeobox transcription factors act as powerful intrinsic agonists of HSC selfrenewal in vitro and in vivo when supplied either as transduced cDNAs or as externally delivered proteins. These findings provide tools for deepening our knowledge of mechanism and for achievement of clinically useful levels of HSC expansion. 
The capacity for sustained self-renewal -the generation of daughter cells having the same regenerative properties as the parent cell -is the hallmark feature of hematopoietic stem cells (HSCs). In the murine system, retroviral marking studies, and more recently reconstitution studies based on injection of single purified HSC, have shown that single HSC can maintain hematopoiesis for the lifetime of a mouse, and that clones established by HSC continue to contain newly generated HSC again capable of regenerating the system (Benveniste et al., 2003) .
Regulation of the self-renewal process in HSC is only dimly understood. As a starting point, early experiments established that self-renewal was indeed subject to extrinsic regulation in vivo. In normal adult mice, the number of HSC in the marrow is relatively constant. In contrast, Sauvageau et al. (1995) , Pawliuk et al. (1996) and Iscove and Nawa (1997) showed that after transplantation of HSC into irradiated mice the number of HSC increased over the number initially injected by 10-20-fold. After the initial weeks, HSCs were maintained at a plateau level. When HSCs were taken from reconstituted mice in the steady state and again injected into irradiated recipients, they again increased 10-fold over the number injected before reaching plateau, an observation that was obtained in four successive serial transfers to achieve a cumulative 8400-fold increase over the number of HSC initiating the series (Iscove and Nawa, 1997) . These experiments showed that the extent of self-renewal in HSC was subject to modulation by cues in the HSC environment, and that normal HSCs could undergo extensive increase in their number.
HSCs can communicate with their external environment in multiple ways including through cell-cell contact, binding to constituents of the extracellular matrix and specific interactions with myriad cell bound and soluble growth factors. Much of the impetus to delineate the nature and role of such interactions is to identify extrinsic regulators that might be harnessed for clinically relevant levels of ex vivo HSC expansion. This has brought major focus on soluble or cell-bound growth factors that promote HSC survival and proliferation and that may influence self-renewal versus differentiation decisions. Here, we survey recent advances in our understanding of growth factors for HSC expansion with an emphasis on recent studies that have gained power through improved methods to phenotype, purify and quantitatively assay HSCs. While much has been learned with regard to factors that can promote the survival and proliferation of HSCs, growth factorstimulated pathways that might promote self-renewal have proven more difficult to elucidate.
Role of 'classic hematopoietic' growth factors
A variety of in vitro culture conditions have now been described that permit enormous expansion of later clonogenic progenitors and substantial expansion of even more primitive cells detected as long-term culture initiating cells Zandstra et al., 1997; Hoffman, 1999) . However, the in vitro expansion of rigorously defined HSC has proven a greater challenge. Indeed, it was only in 1990 in studies exploiting retroviral marking that the first rigorous proof was obtained for the ability of murine HSCs to undergo clonal expansion in vitro in stromal-based long-term culture without the addition of exogenous growth factors (Fraser et al., 1990 (Fraser et al., , 1992 . While these studies provided clear demonstration of in vitro amplification of HSC, overall there was a net decline over input numbers (6.5-fold after 4 weeks), indicating that the culture conditions were suboptimal for stimulating HSC selfrenewal and/or their continued survival.
Later studies have emphasized the use of more purified starting cell populations and stromal-free cultures to investigate the ability of various cytokine cocktails to support HSC growth in vitro. Using a limit dilution assay for competitive repopulating cells (CRU), Miller and Eaves (1997) reported a threefold net increase in vitro of long-term lymphomyeloid repopulating cells following culture in serum-free media with a combination of interleukin-11 (IL-11), Flt3-ligand (FL) and Steel factor (SF). Importantly, these studies further demonstrated that HSCs expanded in vitro were not detectably impaired in their subsequent in vivo regenerative potential (Miller and Eaves, 1997) . Similar experimental strategies were applied to the human model by combining serum-free culture of enriched populations of cord blood CD34 þ CD38 À cells and limit dilution assay for human hematopoietic cells (CRU) capable of repopulating immunodeficient NOD/SCID mice. In two independent studies 2-4-fold net increases in human cord blood CRU were demonstrated after 4 days (Bhatia et al., 1997) or 5-8 days culture in complex growth factor cocktails of FL, SF, G-CSF, IL-3 and IL-6. Again employing rigorous limit dilution assays for human cord blood CRU, Ueda et al. (2000) reported a 4.2-fold expansion of human HSC in 7-day serum-free cultures of CD34 þ cells in a novel cocktail of FL, SF, thrombopoietin (TPO) and interleukin-6 (IL-6) and the soluble IL-6 receptor, the latter included to maximize IL-6 signaling in cells where receptor density might be limiting. Recent studies have also demonstrated ex vivo expansion of human HSC from adult source, specifically adult bone marrow and mobilized peripheral blood (Gammaitoni et al., 2003) . In these latest studies, human adult CRU measured by limit dilution assay in NOD/SCID mice expanded by sixfold after 3 weeks culture in FL, SF, TPO and IL-6, whereas combinations of FL, SF and TPO or FL, SF, TPO and IL-3 were much less effective and at best only resulted in maintenance of input CRU numbers for 1-3 weeks.
Together, the studies described above illustrate encouraging evidence that net expansion of human and murine HSCs is possible in relatively simple, shortterm liquid culture systems. They also however telegraph some continuing major challenges. Despite examination of a wide range of single and complex growth factor cocktails, the magnitude of expansion so far obtained is modest and dramatically less than the readily achievable multilog expansion of later progenitors. A recurring observation also is the inability to sustain the output of rigorously defined repopulating HSC beyond a very limited time in culture (for example, see Bhatia et al., 1997; Ueda et al., 2000) . Questions also remain about optimal choices of growth factors. For example, IL-3 has appeared to have a negative impact on HSC expansion in vitro in some studies (Yonemura et al., 1996; Ueda et al., 2000; Gammaitoni et al., 2003) but not in others (Bhatia et al., 1997; Conneally et al., 1997; Bryder and Jacobsen, 2000) .
Possible explanations for the observed low overall expansion are that HSC are relative unresponsiveness to growth factors currently used to stimulate cell cycle, thus largely remaining quiescent, or loss of engrafting potential once stimulated to proliferate due to differentiation or death. These possibilities have been directly explored by Glimm and Eaves (1999) in elegant studies using loss of (5-and 6-) carboxyfluorescein diacetate succinimidyl ester staining to track and purify primitive human cord blood or fetal liver cells as a function of their proliferative history. Their results provide clear evidence that essentially all cells that were recovered after 5 days suspension culture and subsequently detected in a long-term NOD/SCID repopulating assay had divided at least once. Analogous findings were reported by others using highly purified murine HSC cells placed in single-cell cultures and tracked for cell division and retention of repopulating activity (Ema et al., 2000; Nakauchi et al., 2001) . Thus, limited in vitro HSC expansion is not readily attributable to a failure to induce cycling but rather reflects suboptimal conditions to sustain HSC survival and/or to promote symmetrical self-renewal divisions. Differential effects of hematopoietic growth factors on promoting HSC survival have been documented and it appears that multiple signals may be required to prevent apoptosis (Domen and Weissman, 2000) . Certain factors may also have the ability to impair HSC survival as discussed above for IL-3 and also reported for tumor necrosis factor-alpha Dybedal et al., 2001) .
Perhaps most intriguing is the possibility that growth factors might positively alter self-renewal versus differentiation decisions of stem cells. Iscove and Nawa (1997) observed a twofold enhancement of HSC numbers in reconstituted mice after administration of SF and IL-11. In vivo administration of SF, IL-3, GM-CSF and Epo to NOD/SCID mice that had been repopulated with human cord blood CRU enhanced the number of regenerated human lymphomyeloid CRU that could be detected in secondary mice by B10-fold (Cashman and Eaves, 1999) . Treatment with SF, FL and IL-6 increased human CRU regeneration by B3-fold. Most significantly, these enhanced regenerative effects were observed with administration of growth factors to mice in which human progenitor populations were already known to be maximally cycling, and thus arguing that the underlying mechanism was not at the level of cell cycle per se but rather at the level of selfrenewal decisions (Cashman and Eaves, 1999) . The possibility that exogenous growth factors can differentially affect HSC self-renewal in vitro has been explored by Uchida et al. (2003) 
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þ cells to divide; however, it was only in the first cocktail that the frequency of stem cells detected following first division was preserved. These findings thus suggest that combination growth factor signals can differentially alter HSC self-renewal decisions.
Application of powerful multifactoral design experiments (Audet et al., 2001 (Audet et al., , 2002 is also helping to refine identification and understanding of optimal growth factor combinations to promote self-renewal. Such experiments have revealed, for example, that while FL and SF alone can stimulate over 80% of c-kit þ Sca þ Lin À adult mouse bone marrow to proliferate, retention of stem cell activity requires stimulation by IL-11 or IL-6. Thus, SF and FL appear sufficient to stimulate survival and proliferation, but activation of additional pathways (e.g. through GP130) may be one critical mechanism whereby proliferation is tied to self-renewal over differentiation. These multifactorial design studies also revealed that combinations and concentrations of growth factors are critical. Stimulation of HSC expansion by IL-11 was observed at a very narrow concentration range, whereas for others such as SF or FL saturation effects were not achieved even at high concentrations (4300 ng/ml) (Audet et al., 2002) . The need for careful growth factor 'dosing' is also suggested by the marked impairment of regeneration of human CRU in NOD/SCID transgenic mice expressing high levels of human IL-3, GM-CSF and SF (Nicolini et al., 2004) , and markedly reduced regenerative capacity of HSC from mice lacking SHIP, a key negative regulator of multiple hematopoietic receptors (e.g. for GM-CSF, IL-3, SF) (Helgason et al., 2003) . Thus, unchecked hematopoietic growth factor signaling may be detrimental to HSC. Conversely, recent studies by Fox et al. (2002) show that regeneration of normal HSCs in recipients lacking TPO are impaired by some 10-20-fold, and thus reinforcing the concept that stimulation of selective growth factor pathways can be a crucial determinant of HSC self-renewal (Fox et al., 2002) . Interestingly, TPO has been implicated as a positive regulator of HOXB4 expression, a potent enhancer of HSC expansion (see following section) (Kirito et al., 2003) . Growth factor-mediated activation of transcriptional regulators of HOXB4 (and perhaps other Hox 4th paralog members) including upstream stimulating factors 1 and 2 has also been reported (Giannola et al., 2000; Zhu et al., 2003) . Such findings provide tantalizing evidence of links between hematopoietic cytokines and key transcriptional regulators of HSC function.
Developmental regulators and HSC expansion
Clues to extrinsic mediators of HSC self-renewal are also emerging from a broader understanding of the key receptor signaling pathways involved in the development and maintenance of the hematopoietic system. Here, we briefly describe some recent findings in this context that highlight promising additional avenues to HSC expansion. The large family of fibroblast growth factors (FGFs) has attracted attention based on growing evidence of their possible roles in hematopoiesis. For example, FGFR1
À/À ES cells showed dramatically impaired hematopoietic differentiation in vitro (Faloon et al., 2000) , and chromosomal translocations that result in constitutive activation of the FGFR1 receptor have been identified in myeloproliferative disorders (Guasch et al., 2001) . Recent studies by de Haan et al. (2003) indicate that receptors for FGF-1 are present on primitive hematopoietic cell subsets in addition to some nonhematopoietic bone marrow cells (BMCs). Most strikingly, culture of unfractionated mouse bone marrow in serum-free media supplemented only with FGF-1 resulted in a delayed onset but subsequently large and sustained expansion of cells with lymphoid and myeloid repopulating capacity (de Haan et al., 2003) . Clonal lymphomyeloid potential of the expanded cells was not verified in this study, and thus it is possible that FGF stimulated simultaneous expansion of more restricted lymphoid and myeloid repopulating cells. It is also possible that the effect is indirect since FGF-1-stimulated expansion was not observed using purified HSCs. Despite these caveats, the magnitude and duration of expansion of serially transplantable repopulating cells is striking and suggest that FGF-stimulated pathways warrant further examination.
Transmembrane forms of the hedgehog family of proteins or their cleaved soluble forms have been implicated in early mesoderm and embryonic specification of multiple tissues including hematovascular development (Baron, 2003) . Hedgehog proteins act on their cognate receptor, patch, first recognized in Drosophila, and subsequently through a complex signaling cascade involving the receptor smoothened (Smo) and transcription factors belonging to the Gli family (Baron, 2003; Nusse, 2003) . Bhatia and co-workers (Bhardwaj et al., 2001) have explored the possible role of the hedgehog pathway in hematopoietic cells. Their analyses revealed expression of multiple components of this signaling pathway in human cord blood CD34 þ CD38 À Lin À cells and some committed hematopoietic subsets (Bhardwaj et al., 2001) . Moreover, antibody-mediated blockade of hedgehog signaling and addition of soluble forms of hedgehog had measurable effects on the proliferation and differentiation of primitive human hematopoietic cells (Bhardwaj et al., 2001) . Of particular note, addition of the soluble form of the hedgehog factor, sonic hedgehog, to a cocktail of hematopoietic growth factors (FL, SF, G-CSF, IL-3 and IL-6) enhanced recovery of NOD/SCID repopulating cells from 7-day cultures of human cord blood CD34 þ CD38
À Lin À cells.
Self-renewal of hematopoietic stem cells G Sauvageau et al
Further findings suggest that the stimulatory effects of sonic hedgehog may, in part, be mediated through modulation of bone morphogenic proteins (BMP)4 signaling pathways (Bhardwaj et al., 2001) . BMPs have also been assessed for their possible role in primitive HSC function based on their critical roles in hematopoietic specification from mesoderm during early embryonic development (see Marshall and Thrasher, 2001 for a recent review). Expression of BMP receptors and known downstream signal transducers, such as members of the SMAD family, have been documented in CD34 þ CD38 À Lin À human cord blood cells (Bhatia et al., 1999) . Tests of several BMPs including BMP2, BMP4 and BMP7 in serum-free expansion cultures of CD34 þ CD38 À Lin À human cord blood cells along with multiple hematopoietic cytokines revealed that in a narrow concentration window, BMP4 was unique in its ability to extend the period in which cells with in vivo repopulating potential could be recovered. These studies suggest that BMP4, at a minimum, may serve as an important survival factor for HSC and could be an important component for achieving enhanced stem cell expansion in vitro.
Perhaps, some of the most compelling evidence of early developmental growth factors impacting on HSC self-renewal have come from studies of the Notch receptors and their associated transmembrane ligands such as Jagged 1, Jagged 2 and Delta (reviewed in Kojika and Griffin, 2001 ) and the Frizzled family of receptors and their associated ligands belonging to the Wnt family of soluble growth factors (reviewed in Baron, 2003; Nusse, 2003) . Building on evidence of expression of Notch receptors in primitive hematopoietic cells, Bernstein's group (Varnum-Finney et al., 2000) showed that constitutive expression of the activated form of the Notch1 receptor -the intracellular domain of the Notch1 receptor or ICN1 -led to the generation of cytokine-dependent immortalized cell lines with multipotent repopulating potential. In other studies, Scadden and co-workers (Stier et al., 2002) examined the effect of constitutive expression of ICN1 on transduced murine bone marrow stem cell function following transplantation into mice. The transduced cells were from Rag-1 À/À mice, a mouse line lacking the ability to produce mature B-and T-lymphocytes, thus resistant to ICN1-induced lymphoid leukemogenesis. They observed increases in the HSC pool of repopulated mice both assessed phenotypically and by assays of stem cell regeneration by transplantation into secondary mice.
Evidence that a Notch ligand could be used directly to trigger HSC expansion has been reported recently by Bernstein and co-workers (Varnum-Finney et al., 2003) . For their studies they engineered the Notch1 ligand, Delta1 as a fusion between the extracellular domain of Delta1 and the FC domain of human immunoglobulin, thereby enabling its immobilization on tissue culture plates. Presentation of Delta1 in this immobilized form together with a cocktail of growth factors (SF, FL, IL-6 and IL-11) resulted in a several log increase in the number of cells capable of short-term lymphoid and myeloid repopulation after a 28-day culture. Immobilization of Delta1 appeared to be crucial since soluble forms were without demonstrable effect, perhaps explaining the relatively modest effects previously reported using various soluble or transmembrane forms of Notch ligands (Varnum-Finney et al., 2003) . While expansion of HSC with long-term repopulating capacity was not documented in this study, the accumulated evidence encourages further assessment of the Notch pathway in HSC self-renewal. Supporting this view, recent studies focused on characterization of the so-called 'HSC niche' have also brought attention to the Notch pathway (Calvi et al., 2003; Zhang et al., 2003) . Two different strategies, one involving conditional inactivation of the BMP receptor type 1 A and the other using transgenic mice expressing the constitutively active parathyroid hormone receptor (Calvi et al., 2003) revealed elevations in HSC number (B2-fold) associated with an increase in osteoblastic cells. Interestingly, the osteoblastic cells were found to produce high levels of the Notch ligand, Jagged 1. Further, increased levels of ICN1, evidence of Notch1 activation, were observed in the associated primitive hematopoietic cells. These findings reinforce interest both in the Notch pathways and in further characterization of the HSC microenvironment as a way to identify novel agents for HSC expansion.
The conserved Wnt family of secreted glycoprotein growth factors, their cognate receptors belonging to the Frizzled family and downstream effectors, including b-catenin and the LEF-1 family of transcription factors, are also recognized for their key roles in multiple developmental pathways (Baron, 2003; Nusse, 2003) . The documented expression of multiple members of the Wnt growth factor and Frizzled receptor families, along with early evidence of possible stimulatory effects of Wnt's on hematopoietic progenitors, have prompted considerable interest in this family of growth factors in the context of hematopoiesis (Austin et al., 1997; Van Den Berg et al., 1998) . Bhatia and co-workers (Murdoch et al., 2003) subsequently showed that administration of Wnt5A to mice transplanted with human cord blood cells increased the level of multilineage reconstitution and output of human hematopoietic clonogenic progenitors consistent with stimulatory effects on hematopoietic regeneration. Very recent studies Willert et al., 2003) shed further light on the role of Wnt in hematopoiesis and provide strong support for a direct role in self-renewal of HSCs. The work by Nusse and co-workers showed that Wnt proteins are lipid modified and with this knowledge they developed methods for purification of Wnt3A in biologically active form. Purified Wnt3A was shown to synergize with low doses of SF to induce proliferation of HSC-enriched cells placed in single-cell cultures with retention of their long-term repopulating capacity. Extensive and complementary studies by Weismann and co-workers provided further evidence for a role of Wnt in HSC self-renewal. Retrovirally engineered expression of the constitutively active form of b-catenin, normally generated in response to Wnt signaling, enhanced the proliferation of phenotypically 
Regulation of HSC self-renewal by Hox genes
Hox genes are part of a highly conserved family of transcription factors that contains 39 members clustered on four different chromosomes (McGinnis and Krumlauf, 1992) . These genes encode DNA-binding homeodomain-containing proteins, which play major roles in cell fate determination in lower and higher organisms. In the hematopoietic system, Hox gene expression was first reported by Adams and co-workers (Kongsuwan et al., 1988) , who showed the presence of several Hox transcripts some of which appeared specific to subsets of hematopoietic cells. Hox gene expression was also surveyed in primary BMCs in which the majority of A and B cluster genes were preferentially expressed in primitive subpopulations (Giampaolo et al., 1994 (Giampaolo et al., , 1995 Moretti et al., 1994; Sauvageau et al., 1994; Pineault et al., 2002) . The function of Hox genes in hematopoiesis was initially investigated through overexpression studies (Sauvageau et al., 1995 Thorsteinsdottir et al., 1997; Kroon et al., 1998) . Using retroviral gene transfer, Hoxb4 overexpression was engineered in primary mouse BMCs prior to their injection into irradiated mice in order to produce a series of bone marrow transplantation chimeras. These initial studies involved the use of BMCs isolated from mice injected 4 days earlier with 5-FU, a cytotoxic drug reported to accelerate the recruitment of HSCs into active cell cycling (Harrison and Lerner, 1991) . BMCs were then isolated from these recipients and HSC numbers determined at 3 and 5 months post-transplantation by using limiting dilution analysis (see CRU assay in previous section). These initial studies demonstrated that Hoxb4-overexpressing HSCs were 43-55 times more competitive than untransduced cells in reconstituting the HSC compartment in vivo. In absolute values, Hoxb4-transduced HSCs expanded from 20 to 20 000 or about 3 logs in vivo, whereas control cells, within the same animal, could only expand by B20-fold. This expansion was proven to originate at the level of HSCs as demonstrated by the occurrence of identical proviral integration patterns in myeloid and lymphoid cells within the same mouse (Sauvageau et al., 1995; Thorsteinsdottir et al., 1999) . In addition, enhanced self-renewal was suspected as the mechanism responsible for these observations since several secondary recipients were repopulated with HSC displaying identical proviral integration patterns (Thorsteinsdottir et al., 1999) . Importantly, this Hoxb4 effect occurred on several different HSCs as evidenced by the polyclonal regeneration of the hemopoietic system in 'long-term' recipients of Hoxb4-transduced cells.
The pool size of Hoxb4-transduced HSCs appeared stable between 3 and 5 months in the primary recipients, suggesting that the expansion of these cells was limited in time. To rule out that the HSCs that had undergone this important expansion had exhausted, they were transplanted in secondary and tertiary recipients at limiting numbers. In these experiments, Hoxb4-overexpressing cells again expanded by at least 3 logs (from 5 to 4700 HSCs) (Sauvageau et al., 1995) . Importantly, the pool size of Hoxb4-transduced cells never expanded above that observed in unmanipulated mice or about 20 000 HSCs per mouse in all primary and secondary recipients analysed in these experiments (Sauvageau et al., 1995; Thorsteinsdottir et al., 1999) .
Four important conclusions were derived from these initial studies: First, HSCs engineered to overexpress Hoxb4 were much more competitive in vivo than control cells, and this expansion had the signature of a potential effect on HSC self-renewal; second, the activity of Hoxb4 appeared cell autonomous since it was not transferred to untransduced cells within the same animal; third, the Hoxb4-induced HSC expansion is limited in time; fourth, Hoxb4-transduced cells seemed to respect the mechanisms regulating total HSC numbers in vivo. In line with these results, the incidence of leukemia was not increased in recipients of Hoxb4-transduced cells when compared to age-matched controls exposed to similar experimental conditions. The results summarized in the following paragraphs will provide additional insights into these four conclusions.
Several primary recipients of Hoxb4-transduced cells from the initial cohorts were kept alive for 1 year at which time HSC numbers were reassessed in these mice. As observed with recipients killed at earlier time points, these long-term recipients displayed normal blood counts but contained a 3-5-fold increase in myeloid progenitor numbers, which was most remarkable in their spleens (Sauvageau et al., 1995; Thorsteinsdottir et al., 1999) . HSC numbers in these recipients were not different from that determined at 3 and 5 months, demonstrating that following an initial period of marked expansion, the pool size of Hoxb4-transduced HSC remained stable for at least 1 year in mice (Thorsteinsdottir et al., 1999) . Hematopoietic organs isolated from all of these recipients continued to express high levels of Hoxb4, confirming that Hoxb4-overexpressing HSCs did not continue to expand (Thorsteinsdottir et al., 1999) . From these studies, it was speculated that conditions present during myeloablation, or in vitro during retroviral gene transfer, favored the expansion of Hoxb4-transduced cells and that these conditions were absent in repopulated animals.
Insight into the kinetics of Hoxb4-transduced HSC expansion was gained in a series of experiments where HSC numbers were determined repetitively soon after the generation of the bone marrow transplantation chimeras (Antonchuk et al., 2001) . As early as 14 days post-transplantation, HSC numbers in cohorts of primary recipients of Hoxb4-transduced cells had achieved values representing B25% of the maximal HSC pool size eventually observed in these mice. In absolute terms, an estimated number of 50 Hoxb4-transduced HSCs were injected and B1000 were detected 14 days later for an expansion of approximately 20-fold (Antonchuk et al., 2001) . These cells only expanded a further fourfold in the following 10 weeks, indicating that most of the HSC expansion (self-renewal) occurred during the first 2 weeks. In comparison, only 10 GFP-transduced HSCs were detected per mouse at 14 days, indicating that the control HSCs did not expand during this initial period of time. The kinetics of HSC reconstitution by Hoxb4-versus GFP-transduced cells differed markedly. The former expanded mostly during the first 2 weeks, whereas the latter gradually expanded to reach a plateau at about 3 months. This suggests that conditions present in the animal during the first 2 weeks following myeloablation favored symmetrical self-renewal divisions of Hoxb4-transduced cells (thus expansion) but asymmetrical divisions (thus maintenance) of control cells. Numerically, the number of doublings that distinguishes Hoxb4 versus control GFP-transduced HSCs is rather minimal during these first 2 weeks post-transplantation (4-5 versus 0 for Hoxb4 versus control cells, respectively). The impact of these initial divisions is, however, very impressive when both populations seem to expand slowly at a similar kinetics in the second and third month. Together, these results suggest that the important, but self-limiting, expansion of CRU induced by Hoxb4 might require an environment (e.g. growth factors, etc.) that is only present during the first few weeks that follow bone marrow transplantation (secondary recipients). These results also highlight the potential impact of symmetrical self-renewal divisions occurring early during reconstitution of the HSC compartment.
Thus, post-HSC transplantation, it appears that symmetrical self-renewal divisions of HSCs with maintenance of the expanded stem cells is infrequent unless Hoxb4 is overexpressed in these cells. Interestingly, the impact of Hoxb4 on HSC expansion is inversely proportional to the cell dose transplanted (Antonchuk et al., 2001) . For example, a net B3 log expansion in HSCs is observed when as few as five to 50 Hoxb4-transduced HSCs are transplanted (Antonchuk et al., 2001) . This level of expansion favorably compares to that (B20-fold) occurring when similar numbers of control HSCs are transplanted. However, a mere fivefold expansion in Hoxb4-transduced HSCs is detected when more than 2000 of these cells (representing one-tenth of the entire HSC pool size of a normal mouse) are transplanted. This inverse relation between HSC dose/expansion has been previously reported for normal HSCs whether they are of bone marrow of fetal liver origins (Pawliuk et al., 1996, Iscove and Nawa, 1997) . In the case of normal (untransduced) cells, it is important to stress that the regenerated HSC pool size rarely reach normal values but is rather below that observed in mice that have never been transplanted or exposed to toxic agents (Sauvageau et al., 1995; Pawliuk et al., 1996; Iscove and Nawa, 1997; Antonchuk et al., 2001) . Thus, one key difference in the limitation of expansion between control versus Hoxb4-transduced HSCs could be that niche availability may limit the expansion of the latter, while expansion of the former appears limited by yet to be defined mechanisms that have been apparently overcome as a result of Hoxb4 overexpression.
At least using in vitro targets, HOXB4 binds DNA cooperatively with another group of homeodomaincontaining proteins of the TALE family most notably PBX1, which is implicated in early hematopoiesis (DiMartino et al., 2001) . The presence of PBX1 in the nucleus is dependent on its interaction with MEIS1, another homeodomain protein essential for early hematopoietic development (Hisa et al., 2004) . The HSC-expanding activity of Hoxb4 appears to be DNAbinding dependent since a point mutant in the homeodomain's 51st amino acid, a asparagine residue that directly contacts DNA, abrogates the HSC-expand ing function of this protein (Beslu et al., 2004) . When levels of Pbx1 are experimentally reduced in Hoxb4-overexpressing HSCs, they become about 1-2 logs more competitive than Hoxb4-transduced HSCs when cotransplanted in the same animal. Interestingly, even under these conditions, the peripheral blood cell counts remain normal and, at most, a modest expansion in myeloid and lymphoid progenitors is detected in the bone marrows and spleens from these animals (Krosl et al., 2003b) . These results suggest that HSCs engineered to overexpress Hoxb4 and low levels of Pbx1 (hereafter called HSC Hoxb4hi/Pbx1lo ) expanded faster than those overexpressing Hoxb4 (HSC Hoxb4 ), and were perhaps the first to fill the 'niche'. These experiments further suggested that niche availability is a major determinant in regulating the upper limit of expansion of Hoxb4-transduced HSCs. More importantly, these studies indicate that Hoxb4-transduced cells may be a useful tool for dissecting the extrinsic factors limiting HSC numbers in vivo. These studies also suggest that without this in vivo 'barrier' to HSC expansion, it may be possible to generate even larger numbers of HSCs (e.g. in vitro).
The expansion of Hoxb4-transduced HSCs was also assessed in vitro where the mechanisms limiting their in vivo expansion may not operate. BMCs transduced with Hoxb4, or a control retrovirus, were maintained in vitro for a total of 12 days in the presence of serum and HSC numbers determined at selected time points. Results from these experiments indicated that cultures initiated with very large numbers of Hoxb4-transduced cells showed a net 5-7-fold increase in HSC numbers at day 6 and a 40-fold increase by day 12. These results are most interesting considering that cultures were initiated with high HSC numbers (i.e. 7000), which would not expand much at this cell dose if transplanted into irradiated mice (see previous paragraph). In these same cultures, the number of control (i.e. untransduced or GFP-transduced) HSCs decreased by 7-10-fold at day 6 and by 30-60-fold at day 12. Thus, in these conditions, Hoxb4 overexpression was capable of inducing major HSC expansion even if the number of HSCs initiating the cultures was very high. These results also show that these culture conditions were suboptimal for control cells. Thus, Hoxb4 induces self-renewal in vitro even in conditions that are suboptimal for untransduced HSCs. More importantly, these results suggest that the limit imposed in vivo is not present in vitro where it was possible to expand large number of HSCs overexpressing Hoxb4. Based on these results, it can be assumed that the ultra-competitive HSC Hoxb4hi/Pbx1lo cells will dramatically expand when tested under similar in vitro conditions. Thus, Hoxb4/Pbx1-based strategies should allow unprecedented HSC expansion leading to clinically applicable protocols (S Cellot, J Krosl et al., in progress) .
Several observations suggest that it might be possible to develop methods allowing the in vitro expansion of HSCs using direct delivery of a recombinant HOXB4 protein. First, as detailed in the previous paragraphs, this protein has an impressive impact of HSC expansion both in vivo and in vitro (Sauvageau et al., 1995; Antonchuk et al., 2002) . Second, most of the expansion of Hoxb4-transduced HSCs occurs rapidly after transplantation (Antonchuk et al., 2001) . Third, Hoxb4 contains a conserved motif in the third helix of its homeodomain known as penetratin (Joliot and Prochiantz, 2004) . This domain introduces cargo proteins into live cells when ectopically fused. One hypothesis was therefore that recombinant Hoxb4 proteins might be derived to enhance HSC expansion in vitro and possibly in vivo. This hypothesis was independently tested by two groups: one using the bacterially produced Hoxb4 protein fused to a small peptide derived from HIV TAT protein (Krosl et al., 2003a) and the other using a HOXB4 protein secreted by 'feeder' cells (Amsellem et al., 2003) . In the latter case, the HOXB4 protein was fused to an export sequence from an immunoglobulin light chain and tested on human cells (see next section on human cells). The TAT-HOXB4 protein was tested using sorted mouse BMCs enriched for HSC activity. First, it was found that HSC expansion by TAT-HOXB4 could only be achieved when appropriate protein levels, corresponding between 10 and 100 mmol, were used. Levels of 2 mmol were insufficient and preliminary results clearly suggest that excessive levels are toxic (see last section). Once appropriate levels of the recombinant protein were determined, cells were exposed TAT-HOXB4 for 4 days and HSC numbers determined before and after the cultures. The results indicated that TAT-HOXB4 contributed to a net fivefold expansion of HSCs (Krosl et al., 2003a) . As expected from earlier studies, a decline in HSC numbers was measured in control cultures (containing TAT-GFP) for net differences in HSC content exceeding 10-fold between cultures exposed or not to TAT-HOXB4, respectively. The expansion of transplantable HSCs reported with the protein was comparable to that described with retrovirally transduced cells (i.e. B5-fold in 4-to 6-day cultures). Similar protein-based strategies to inhibit Pbx1 activity are also being developed. Together, these studies indicate that it is now possible to expand significantly mouse HSCs using deliverable proteins. It will be essential to determine whether these findings, performed with mouse cells, are also applicable to human HSCs.
From the work described above, it is clear that both Hoxb4 and PBX1 affect essential mechanisms governing HSC self-renewal in mouse. If applicable to human HSCs, these results would have numerous clinical implications. Although the human studies have been initially hampered by technical difficulties in cell transduction, recent progress in lentiviral and adenoviral vectors in addition to possibilities of direct protein delivery now offers many avenues for testing Hoxb4-induced expansion of human HSCs. Four studies with different experimental designs and vectors have been reported so far, all performed using cord blood. Buske et al. (2002) used a Moloney-based (MSCV) viral vector to engineer the expression of Hoxb4 in cord blood. As found with mouse cells, they observed an increase in replating capacity of colony-forming cells and a 5-10-fold expansion in long-term culture-initiating cells (LTC-IC) over 2-7 days of culture (expansion of mouse LTC-IC: U Thorsteinsdottir, GS and KH, unpublished) . Interestingly, they also reported a fourfold expansion of primitive cells capable of initiating long-term repopulation of the NOD-SCID mouse (the so-called NOD-SCID repopulating cells or SRC) within 24 h of in vitro culture. Extended in vitro cultures are needed to determine the magnitude of expansion that can be achieved with SRCs engineered to overexpress Hoxb4. Schiedlmeier et al. (2003) recently reported results with cord blood cells engineered to overexpress a range of levels of Hoxb4 by using different strategies including the generation of a GFP-FMDV 2A esterase-Hoxb4 fusion gene subcloned into different retroviral vectors including FMEV/MESV hybrids. Their results indicate that primitive (CD34 þ ) human cells expressing Hoxb4 expand significantly in NOD-SCID mice, but differentiation of these cells into lymphoid and myeloerythroid lineages was impaired when levels of Hoxb4 were high. A GFP-2A-HOXB4 fusion protein (B75 kDa) was also generated by these constructs and may complicate the interpretation of the results. Buske et al. (2002) reported a Hoxb4-dependent 30-fold increase in CD34 þ CD19 þ B cells in vivo (see Table 1 for summary). Brun et al. (2003) described the use of an adenoviral vector system to engineer transient overexpression of Hoxb4 in CD34
þ cord blood cells and found no increase in proliferation of primitive progenitors or frequency of colony-forming cells. Instead, they observed an increase in cells expressing differentiation markers of the myeloid lineages. LTC-ICs were also apparently reduced in cultures initiated with cells transduced with Hoxb4. Importantly, the expression levels of Hoxb4 achieved in these studies is difficult to compare with that achieved with retroviruses. Also, the use of adenoviruses to engineer Hoxb4 overexpression has not yet been tested with mouse cells. Amsellem et al. (2003) generated an MS-5 stromal cell line engineered to secrete HOXB4 and showed that the secreted protein was incorporated into the cultured hematopoietic cells. Using a 5-week long-term culture system, they used limit dilution analysis to show a fourfold increase in LTC-IC and a twofold increase in SRC. Thus, the presence of the HOXB4 recombinant protein in the medium was compatible with SRC expansion and did not appear to interfere with myeloid or lymphoid differentiation.
Thus, as observed with mouse cells, it appears that Hoxb4 overexpression will lead to the expansion of primitive human cells. From the available studies, it is obvious that many parameters will need to be optimized. The recombinant TAT-HOXB4 should prove useful to accelerate this optimization process. As detailed below, several problems inherent to HOXB4 will need to be addressed before this technology is ready for clinical application.
Based on many years of research on Hoxb4, much knowledge has been accumulated, but many questions and challenges remain. It will be important to continue investing concerted efforts in the applicability of this technology to human HSCs. Preliminary studies indicate that TAT-HOXB4 may be very effective in expanding cells isolated from mobilized blood. (Roy DC, Krosl G and Sauvageau G, unpublished observation) Does this reflect a restricted effect of Hoxb4 on activated (G-CSF) cells? Ongoing studies also indicate that HOXB4 is a very unstable protein (half-life less than 1 h) and we recently identified a single residue in the N-terminal portion of the protein essential for much of this instability. It will be important to test whether the mutated stable protein preserves all of the activity of Hoxb4. Recent studies also indicate that the DNAbinding capacity of HOXB4 is essential for its activity on HSCs. This presupposes the existence of target genes that would be essential to characterize. These targets will most certainly be shared with other homeodomain proteins such as HOXA9, which also possess HSCexpanding activity. The uniqueness of Hoxb4 lies in the fact that it is the only homeobox gene characterized to date which does not cause leukemia. This clearly indicates that enhancement of self-renewal is not sufficient to induce leukemia.
Conclusions
There is now abundant evidence that the self-renewal of HSC is subject to biological control: stability of the numbers of HSC in the normal steady state in vivo, the responsiveness of HSC self-renewal to cues in the transplant host and the capacity of specific ligands to influence self-renewal in culture independently of effects on growth or survival. The remarkable capacity of specific HOX proteins to enhance self-renewal provides a powerful experimental handle for exploration of mechanism and of potential clinical utility. Much effort remains to assemble the various clues into a coherent model of the network controlling HSC renewal in vivo. Twofold increase in TNC, CFC and fourfold increase in LTC-IC after 5 weeks on stroma Twofold increase in CRU after 2 or 5 weeks on stroma Self-renewal of hematopoietic stem cells G Sauvageau et al
